Recurrent VTE in patients with thrombophilia after stopping anticoagulation: a systematic review and meta-analysis.
Kristina Vrotniakaite-Bajerciene, Tzu-Fei Wang, Elham Sabri et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the risk of recurrent venous thromboembolism (VTE) after stopping anticoagulation in patients with hereditary and acquired thrombophilia. Analyzing data from 51 studies involving 34,623 patients, the findings indicate that thrombophilias such as antiphospholipid syndrome and antithrombin deficiency are linked to a twofold to threefold increased risk of recurrent VTE, while heterozygous factor V Leiden or prothrombin mutations are associated with a 1.5-fold increased risk.
Key findings
- Thrombophilias like APS and ATD are linked to a twofold to threefold increased risk of recurrent VTE.
- Heterozygous FVL or PTM mutations are associated with a 1.5-fold increased risk of recurrent VTE.
- The study included 51 studies with a total of 34,623 patients.
- Evidence regarding protein S and C deficiencies was inconclusive.
Why it matters
Understanding the association between thrombophilia and recurrent VTE is crucial for clinicians in making informed decisions about anticoagulation management and secondary prevention strategies in affected patients.